ATE426001T1 - Mittel zur verhinderung und behandlung von sexuell ubertragenen krankheiten-i - Google Patents

Mittel zur verhinderung und behandlung von sexuell ubertragenen krankheiten-i

Info

Publication number
ATE426001T1
ATE426001T1 AT02713925T AT02713925T ATE426001T1 AT E426001 T1 ATE426001 T1 AT E426001T1 AT 02713925 T AT02713925 T AT 02713925T AT 02713925 T AT02713925 T AT 02713925T AT E426001 T1 ATE426001 T1 AT E426001T1
Authority
AT
Austria
Prior art keywords
sexually transmitted
agents
preventing
transmitted diseases
treating sexually
Prior art date
Application number
AT02713925T
Other languages
English (en)
Inventor
Barry Matthews
George Holan
Peter Karellas
Scott Henderson
David O'keefe
Original Assignee
Starpharma Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Starpharma Pty Ltd filed Critical Starpharma Pty Ltd
Application granted granted Critical
Publication of ATE426001T1 publication Critical patent/ATE426001T1/de

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/48—Polymers modified by chemical after-treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/595—Polyamides, e.g. nylon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
    • C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
    • C08G69/10—Alpha-amino-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
    • C08G83/002—Dendritic macromolecules
    • C08G83/003—Dendrimers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/754—Dendrimer, i.e. serially branching or "tree-like" structure
AT02713925T 2001-03-30 2002-03-28 Mittel zur verhinderung und behandlung von sexuell ubertragenen krankheiten-i ATE426001T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPR4128A AUPR412801A0 (en) 2001-03-30 2001-03-30 Agent for the prevention and treatment of sexually transmitted disease s - I

Publications (1)

Publication Number Publication Date
ATE426001T1 true ATE426001T1 (de) 2009-04-15

Family

ID=3828128

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02713925T ATE426001T1 (de) 2001-03-30 2002-03-28 Mittel zur verhinderung und behandlung von sexuell ubertragenen krankheiten-i

Country Status (15)

Country Link
US (2) US7589056B2 (de)
EP (1) EP1399499B1 (de)
JP (1) JP4216076B2 (de)
KR (1) KR100882343B1 (de)
CN (1) CN1305931C (de)
AT (1) ATE426001T1 (de)
AU (2) AUPR412801A0 (de)
BR (1) BRPI0208411B8 (de)
CA (1) CA2441357C (de)
DE (1) DE60231616D1 (de)
ES (1) ES2324600T3 (de)
HK (1) HK1064108A1 (de)
MX (1) MXPA03008909A (de)
NZ (1) NZ528230A (de)
WO (1) WO2002079299A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10179159B2 (en) 1999-10-22 2019-01-15 Scott Wepfer Topical anesthetic formulation
CN1778967B (zh) * 2004-11-25 2010-11-10 中国科学院化学研究所 抑制hiv-1反式激活蛋白与反式激活应答序列rna结合用的聚酰胺-胺型树状化合物
CN101365462A (zh) * 2005-10-18 2009-02-11 星药股份有限公司 杀微生物的树枝状大分子组合物递送系统
EP1981512B1 (de) 2006-01-20 2022-11-02 Starpharma Pty Limited Modifiziertes makromolekül
EP1996209B1 (de) * 2006-03-22 2015-11-04 Starpharma Pty Limited Kontrazeptive zusammensetzung
EP2076557A4 (de) * 2006-08-11 2012-08-29 Starpharma Pty Ltd Polylysindendrimer-kontrastmittel
WO2008017125A1 (en) * 2006-08-11 2008-02-14 Starpharma Pty Ltd Targeted polylysine dendrimer therapeutic agent
JP2008202025A (ja) * 2007-01-22 2008-09-04 Honda Motor Co Ltd プロトン伝導性高分子
JP2008270177A (ja) 2007-03-23 2008-11-06 Honda Motor Co Ltd プロトン伝導体
IT1395137B1 (it) 2009-08-05 2012-09-05 Spider Biotech S R L Nuovi peptidi antipatogeni
US8251452B2 (en) * 2009-11-13 2012-08-28 Hill Jason D Gaming chairs
CN107669698A (zh) 2011-05-16 2018-02-09 星法马私人有限公司 治疗或预防细菌性阴道病的方法
EP2895161B1 (de) * 2012-09-13 2017-05-03 Starpharma Pty Limited Verfahren zur behandlung oder prophylaxe von infektionen des auges
MX2018013373A (es) * 2016-05-05 2019-06-10 Starpharma Pty Ltd Metodo de profilaxis de la infeccion por virus zika.
CN110305188B (zh) * 2018-03-23 2020-03-13 广州朗圣药业有限公司 一种预防hiv感染的新化合物及其制备方法
EP3823961A4 (de) * 2018-07-19 2022-06-08 Starpharma Pty Limited Therapeutisches dendrimer
CN114053392A (zh) * 2020-07-30 2022-02-18 广州朗圣药业有限公司 新型化合物在制备预防和/或治疗hpv感染的药物中的应用
CN114053394A (zh) * 2020-07-30 2022-02-18 广州朗圣药业有限公司 新型化合物在制备预防和/或治疗冠状病毒感染的药物中的应用
CN114053393A (zh) * 2020-07-30 2022-02-18 广州朗圣药业有限公司 一种药物组合物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4289872A (en) * 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
US4410688A (en) * 1981-04-29 1983-10-18 Allied Corporation Macromolecular highly branched homogeneous compound
US4507466A (en) * 1983-01-07 1985-03-26 The Dow Chemical Corporation Dense star polymers having core, core branches, terminal groups
US4558120A (en) * 1983-01-07 1985-12-10 The Dow Chemical Company Dense star polymer
US4568737A (en) * 1983-01-07 1986-02-04 The Dow Chemical Company Dense star polymers and dendrimers
US4587329A (en) * 1984-08-17 1986-05-06 The Dow Chemical Company Dense star polymers having two dimensional molecular diameter
AUPM623994A0 (en) * 1994-06-15 1994-07-07 Biomolecular Research Institute Limited Antiviral dendrimers
AUPO104496A0 (en) * 1996-07-17 1996-08-08 Biomolecular Research Institute Limited Angiogenic inhibitory compounds
US6676946B2 (en) * 1997-03-27 2004-01-13 Institut Pasteur Multiple antigen glycopeptide carbohydrate vaccine comprising the same and use thereof
AUPP584298A0 (en) * 1998-09-14 1998-10-08 Starpharma Limited Antimicrobial and antiparasitic agents
US7572459B2 (en) * 1998-09-14 2009-08-11 Starpharma Pty Ltd. Anionic or cationic dendrimer antimicrobial or antiparasitic compositions
AUPP584398A0 (en) * 1998-09-14 1998-10-08 Starpharma Limited Inhibition of toxic materials or substances
US7030097B1 (en) * 1999-07-14 2006-04-18 Cornell Research Foundation, Inc. Controlled nucleic acid delivery systems
CA2391954A1 (en) * 1999-11-18 2001-05-25 Exxon Chemical Patents, Inc. Method for the synthesis of molecular sieves
US6893506B2 (en) * 2002-03-11 2005-05-17 Micron Technology, Inc. Atomic layer deposition apparatus and method

Also Published As

Publication number Publication date
CN1305931C (zh) 2007-03-21
US7589056B2 (en) 2009-09-15
EP1399499A4 (de) 2004-09-29
US20090269298A1 (en) 2009-10-29
AU2002245932B2 (en) 2007-04-05
US20050008611A1 (en) 2005-01-13
ES2324600T3 (es) 2009-08-11
BR0208411A (pt) 2004-03-30
NZ528230A (en) 2006-02-24
KR100882343B1 (ko) 2009-02-12
WO2002079299A1 (en) 2002-10-10
JP4216076B2 (ja) 2009-01-28
HK1064108A1 (en) 2005-01-21
AUPR412801A0 (en) 2001-05-03
BRPI0208411B8 (pt) 2021-05-25
CA2441357C (en) 2011-05-31
CA2441357A1 (en) 2002-10-10
US8158575B2 (en) 2012-04-17
EP1399499B1 (de) 2009-03-18
MXPA03008909A (es) 2005-03-07
EP1399499A1 (de) 2004-03-24
KR20040027506A (ko) 2004-04-01
BRPI0208411B1 (pt) 2016-06-28
DE60231616D1 (de) 2009-04-30
CN1503816A (zh) 2004-06-09
JP2004532211A (ja) 2004-10-21

Similar Documents

Publication Publication Date Title
ATE426001T1 (de) Mittel zur verhinderung und behandlung von sexuell ubertragenen krankheiten-i
ATE316786T1 (de) Behandlung von mukositis
ATE376835T1 (de) Verwendung von fucanen in der behandlung von adhäsion, arthritis und psoriasis
DE60120667D1 (de) Methoden und mittel zur behandlung von bandscheibenverschleiss
ATE448775T1 (de) Rifalazil zur behandlung von infektionen mit clostridium difficile
BR0210335A (pt) Copolìmero de blocos, e, composição
DE69919868D1 (de) Oregano zur behandlung interner parasiten und protozoen
ATE319439T1 (de) Mittel zur behandlung von erkrankungen des tracheo-bronchialtraktes, insbesondere der copd
DE50209139D1 (de) Zweikomponenten-Mittel mit zeitlichem pH-Gradienten und Verfahren zur Behandlung von Haaren
ATE291927T1 (de) Peptide zur behandlung von beeinträchtigten zwischenmenschlischen störungen und verhaltenstörungen
DE60139783D1 (de) Gen und pflanzenextrakte, wirksam zur behandlung und prävention von chlamydieninfektionen
ATE359816T1 (de) Verfahren zur prävention und behandlung von infektionen mit dem flavivirus bei tieren
DE59903778D1 (de) Mittel zur wasserbehandlung
DE69934096D1 (de) Zusammensetzungen und methoden zur wundheilung
ATE258793T1 (de) 5-ht2 agonisten als mittel zur kontrolle des augeninnendrucks und zur behandlung von glaukom
DE60142786D1 (de) Zusammensetzungen und methoden zur behandlung von candidosen
ATE359808T1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
ATE291425T1 (de) R-eliprodil zur behandlung von glaucoma
MXPA04010816A (es) Acidos aminoalcanfosfonicos sustituidos para el tratamiento de dolor neuropatico, trastornos afectivos y de la atencion, esquizofrenia, tinitus, miopia y otros trastornos oculares.
ATE360425T1 (de) Verwendung von quetiapin für die behandlung von kokain-abhängigkeit
DE60137506D1 (de) Verwendung von polysulfatierten cyclodextrinen zur behandlung von arthrose
SE0003126D0 (sv) Method of treatment
ATE412423T1 (de) Peroxiredoxin-arzneistoffe zur behandlung einer hiv-1-infektion
ATE387913T1 (de) Xenogene oligo- oder/und polyribonukleotide als mittel zur behandlung von malignen tumoren
ATE533480T1 (de) Zusammensetzung zur behandlung von hämorrhoiden

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties